Waigamicin Gel is a topical formulation containing Clindamycin 1% w/w and Nicotinamide 4% w/w, designed for the management of acne vulgaris and other inflammatory skin conditions. Clindamycin, a lincosamide antibiotic, exhibits bacteriostatic activity by inhibiting bacterial protein synthesis, primarily targeting Propionibacterium acnes, a key pathogen in acne pathogenesis. Nicotinamide, a form of vitamin B3, possesses anti-inflammatory, antioxidant, and sebum-regulating properties, which help reduce erythema, hyperpigmentation, and skin irritation associated with acne lesions. The combination of these active ingredients offers a dual mechanism of action, addressing both microbial colonization and inflammatory processes. Waigamicin Gel is indicated for topical use in mild to moderate inflammatory acne, including papules and pustules. It is applied once or twice daily to the affected areas after cleansing, avoiding contact with eyes and mucous membranes. Common adverse effects may include mild skin irritation, dryness, or erythema at the application site. Use during pregnancy or lactation should be under medical supervision. Patients are advised to adhere to prescribed usage and avoid excessive sun exposure during treatment. Waigamicin Gel provides an effective therapeutic option for acne management by combining antimicrobial and anti-inflammatory benefits in a well-tolerated topical gel.